MedTrace Logo

Trandolapril 4 mg Tablet Under Non-Fasting Conditions

NCT00840073 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-08-20

Study results available
· View outcomes & findings →

Summary

The objective of this study is to evaluate the comparative bioavailability between trandolapril 4 mg tablets (test) and Mavik® 4 mg Tablets (reference) after a single-dose in healthy subjects under fed conditions.

Conditions

  • Healthy

Interventions

DRUG

Trandolapril 4 mg Tablets

1 x 4 mg, single-dose fed

DRUG

Mavik® 4 mg Tablets

1 x 4 mg, single-dose fed

Sponsors & Collaborators

  • Teva Pharmaceuticals USA

    lead INDUSTRY

Principal Investigators

  • Xueyu (Eric) Chen, M.D., Ph. D. · Pharma Medica

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-10-31
Primary Completion
2004-11-30
Completion
2004-11-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00840073 on ClinicalTrials.gov